GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » VolitionRX Ltd (AMEX:VNRX) » Definitions » Asset Turnover

VolitionRX (VolitionRX) Asset Turnover : 0.01 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is VolitionRX Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. VolitionRX's Revenue for the three months ended in Mar. 2024 was $0.17 Mil. VolitionRX's Total Assets for the quarter that ended in Mar. 2024 was $23.69 Mil. Therefore, VolitionRX's Asset Turnover for the quarter that ended in Mar. 2024 was 0.01.

Asset Turnover is linked to ROE % through Du Pont Formula. VolitionRX's annualized ROE % for the quarter that ended in Mar. 2024 was 285.97%. It is also linked to ROA % through Du Pont Formula. VolitionRX's annualized ROA % for the quarter that ended in Mar. 2024 was -141.26%.


VolitionRX Asset Turnover Historical Data

The historical data trend for VolitionRX's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VolitionRX Asset Turnover Chart

VolitionRX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.01 0.03

VolitionRX Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Competitive Comparison of VolitionRX's Asset Turnover

For the Diagnostics & Research subindustry, VolitionRX's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VolitionRX's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, VolitionRX's Asset Turnover distribution charts can be found below:

* The bar in red indicates where VolitionRX's Asset Turnover falls into.



VolitionRX Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

VolitionRX's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.775/( (18.295+27.95)/ 2 )
=0.775/23.1225
=0.03

VolitionRX's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0.172/( (27.95+19.435)/ 2 )
=0.172/23.6925
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


VolitionRX  (AMEX:VNRX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

VolitionRX's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-33.468/-11.7035
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-33.468 / 0.688)*(0.688 / 23.6925)*(23.6925/ -11.7035)
=Net Margin %*Asset Turnover*Equity Multiplier
=-4864.53 %*0.029*-2.0244
=ROA %*Equity Multiplier
=-141.26 %*-2.0244
=285.97 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

VolitionRX's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-33.468/23.6925
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-33.468 / 0.688)*(0.688 / 23.6925)
=Net Margin %*Asset Turnover
=-4864.53 %*0.029
=-141.26 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


VolitionRX Asset Turnover Related Terms

Thank you for viewing the detailed overview of VolitionRX's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


VolitionRX (VolitionRX) Business Description

Traded in Other Exchanges
N/A
Address
1489 West Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
VolitionRX Ltd is a United states based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Executives
Eight Corp Ltd 10 percent owner C/O CROWE MORGAN, 8 ST. GEORGE'S STREET, DOUGLAS Y8 IM1 1AH
Salvatore Thomas Butera director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Rodney Gerard Rootsaert director, officer: SECRETARY 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Cameron John Reynolds director, officer: PRESIDENT AND CEO 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Guy Archibald Innes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Edward Futcher director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Phillip Barnes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Martin Charles Faulkes director 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Mickie Henshall director 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Jacob Vincent Micallef officer: Chief Scientific Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Michel Gaetan other: Manager Belgian Volition SPRL 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Jasmine Kway other: CEO-Singapore Volition 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Nicholas Plummer officer: GC - Volition Diagnostics 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014
Ann-louise Batchelor officer: Group Chief Marketing Officer 1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON NV 89014
Terrell Jason Bradley Md officer: Chief Medical Officer 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON NV 89014